Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons.
Stimulating the production of fetal hemoglobin may benefit patients with sickle cell anemia by inhibiting sickling. We gave pulsed treatments with high doses of recombinant human erythropoietin to baboons in order to test the hypothesis that the resultant rapid erythroid regeneration would stimulate F cells--i.e., cells that contain fetal hemoglobin. In normal animals, this treatment caused sharp increments in F-reticulocyte levels, which rose from 1 to 2 percent before treatment to 40 to 50 percent afterward. In two animals with chronic anemia and high levels of endogenous erythropoietin, recombinant human erythropoietin induced further increments in F-reticulocyte levels, which rose in one animal from 6 to 8 percent before treatment to 23 percent after treatment, and in the other from 20 percent before to 50 percent afterward. The time course of F-reticulocyte stimulation suggested that these cells were the products of mobilized early erythroid progenitors. These results raise the possibility that pulses of erythropoietin could be used to stimulate F-cell formation in patients with sickle cell disease.
D000747:Anemia, Hypochromic / Q000097:blood; D000755:Anemia, Sickle Cell / Q000188:drug therapy; D000818:Animals; D004906:Erythrocyte Count; D004921:Erythropoietin / Q000494:pharmacology* / Q000627:therapeutic use; D005319:Fetal Hemoglobin / Q000096:biosynthesis*; D006801:Humans; D010215:Papio; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012156:Reticulocytes; D013268:Stimulation, Chemical
D011994:Recombinant Proteins; D004921:Erythropoietin; D005319:Fetal Hemoglobin